GR107719B Formulation 2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GR107719B Formulation 2, covering 2017-05-15 to 2017-05-15. Get the full timeline:
Most recent: Clinical Trial Update: A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions [Phase 1]